Difference between revisions of "Vincristine (Oncovin)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "'''contains dosing details in manuscript'''" to "'''dosing details in manuscript have been reviewed by our editors'''")
 
(73 intermediate revisions by 3 users not shown)
Line 1: Line 1:
 
==General information==
 
==General information==
−
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.<ref name="insert">[http://patient.cancerconsultants.com/druginserts/Vincristine.pdf Vincristine (Oncovin) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/vincristine.pdf Vincristine (Oncovin) package insert (locally hosted backup)]</ref>
+
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.<ref name="insert">[http://patient.cancerconsultants.com/druginserts/Vincristine.pdf Vincristine (Oncovin) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/vincristine.pdf Vincristine (Oncovin) package insert (locally hosted backup)]</ref>
 
<br>Route: IV
 
<br>Route: IV
 
<br>Extravasation: [[vesicant]]
 
<br>Extravasation: [[vesicant]]
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.<ref name="insert"></ref>  
 +
 
 +
==Diseases for which it is established ''(work in progress)''==
 +
*Non-Hodgkin lymphoma
 +
**[[Follicular lymphoma]]
 +
**[[Mantle cell lymphoma]]
 +
**[[Peripheral T-cell lymphoma]]
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
 
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3">
 
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3">
−
*[[Acute lymphocytic leukemia]]
+
*[[Adult T-cell leukemia-lymphoma]]
 +
*[[Anaplastic glioma]]
 
*[[Anaplastic large cell lymphoma]]
 
*[[Anaplastic large cell lymphoma]]
−
*[[Bone cancer]]
+
*[[B-cell acute lymphoblastic leukemia]]
 
*[[Burkitt lymphoma]]
 
*[[Burkitt lymphoma]]
−
*[[Central nervous system (CNS) cancer]]
 
−
*[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]]
 
 
*[[CNS lymphoma]]
 
*[[CNS lymphoma]]
 
*[[Diffuse large B-cell lymphoma]]
 
*[[Diffuse large B-cell lymphoma]]
−
*[[Extranodal NK/T-cell lymphoma, nasal type]]
+
*[[Ewing sarcoma]]
−
*[[Follicular lymphoma]]
+
*[[Extranodal NK- and T-cell lymphoma, nasal type]]
 +
*[[Gestational trophoblastic neoplasia]]
 +
*[[Glioblastoma]]
 +
*[[Hepatoblastoma]]
 
*[[HIV-associated lymphoma]]
 
*[[HIV-associated lymphoma]]
−
*[[Hodgkin lymphoma]]
+
*[[Classical Hodgkin lymphoma]]
 
*[[Hodgkin lymphoma, nodular lymphocyte-predominant]]
 
*[[Hodgkin lymphoma, nodular lymphocyte-predominant]]
−
*[[Mantle cell lymphoma]]
+
*[[Kaposi sarcoma]]
 +
*[[Low-grade glioma]]
 +
**[[Low-grade glioma, pediatric]]
 
*[[Marginal zone lymphoma]]
 
*[[Marginal zone lymphoma]]
 
*[[Mediastinal gray-zone lymphoma]]
 
*[[Mediastinal gray-zone lymphoma]]
 +
*[[Medulloblastoma]]
 
*[[Multiple myeloma]]
 
*[[Multiple myeloma]]
−
*[[Neuroendocrine tumors]]
+
*[[Neuroblastoma]]
 
*[[Penile cancer]]
 
*[[Penile cancer]]
−
*[[Peripheral T-cell lymphoma]]
+
*[[Pheochromocytoma]]
−
*[[Sarcoma]]
+
*[[Post-transplant lymphoproliferative disorder]]
−
*[[Small cell lung cancer]]
+
*[[Primary mediastinal B-cell lymphoma]]
−
*[[Thrombotic thrombocytopenic purpura]]
+
*[[Rhabdomyosarcoma]]
 +
*[[Soft tissue sarcoma]]
 +
*[[T-cell acute lymphoblastic leukemia]]
 +
*[[Testicular cancer]]
 +
*[[Acquired thrombotic thrombocytopenic purpura]]
 
*[[Thymoma]]
 
*[[Thymoma]]
−
*[[Transplant conditioning regimens]]
+
*[[Transformed lymphoma]]
 +
*[[Waldenström macroglobulinemia]]
 +
*[[Wilms tumor]]
 
</div>
 
</div>
 +
 +
==Diseases for which it was used==
 +
*[[Acute myeloid leukemia - historical|Acute myeloid leukemia]]
 +
*[[Breast cancer_-_historical|Breast cancer]]
 +
*[[Chronic lymphocytic leukemia - historical|Chronic lymphocytic leukemia]]
 +
*[[Chronic myeloid leukemia - historical|Chronic myeloid leukemia]]
 +
*[[Colon cancer - historical|Colon cancer]]
 +
*[[Head and neck cancer - historical|Head and neck cancer]]
 +
*[[Melanoma - historical|Melanoma]]
 +
*[[Osteosarcoma - historical|Osteosarcoma]]
 +
*[[Small cell lung cancer - historical|Small cell lung cancer]]
  
 
==Notable side effects==
 
==Notable side effects==
−
*Neuropathy <ref>Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010 Nov;11(11):1057-65. Epub 2010 Sep 21. [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2810%2970206-0/fulltext link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20864405 PubMed]</ref>
+
*Neuropathy <ref>Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010 Nov;11(11):1057-65. Epub 2010 Sep 21. [https://doi.org/10.1016/S1470-2045%2810%2970206-0 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/20864405/ PubMed]</ref>
  
 
==Patient drug information==
 
==Patient drug information==
Line 43: Line 71:
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
* 7/10/1963: Initial FDA approval
+
* 1963-07-10: Initial FDA approval
−
 
+
*2014-08-05 (oldest label available at Drugs @ FDA): Indicated in [[:Category:Acute leukemias|acute leukemia]]. It has also been shown to be useful in combination with other oncolytic agents in [[Classical Hodgkin lymphoma|Hodgkin’s disease]], [[:Category:Non-Hodgkin lymphomas|non-Hodgkin’s malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types)]], [[rhabdomyosarcoma]], [[neuroblastoma]], and [[Wilms tumor|Wilms’ tumor]]. ''(No supporting studies are cited)''
 +
==History of changes in EMA indication==
 +
*1995-04-12: EURD
 +
==History of changes in PMDA indication==
 +
*2013-03-25: New additional indication and a new dosage for the treatment of [[pheochromocytoma]].
 
==Also known as==
 
==Also known as==
−
Precise Name: vinCRIStine Sulfate (RXCUI 11203)
+
*'''Generic names:''' LCR, leurocristine, VCR, vincristine sulfate
−
 
+
*'''Brand names:'''
−
{| border="1" style="text-align:center;"
+
{| class="wikitable" style="text-align:center;"
 
!colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms'''
 
!colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms'''
 
|-
 
|-
Line 56: Line 88:
 
|Cellcristin
 
|Cellcristin
 
|Citomid
 
|Citomid
−
|Citomid RU
 
 
|Crivosin
 
|Crivosin
−
|Cytomid
 
−
|-
 
 
|Farmistin CS
 
|Farmistin CS
 
|Fauldvincri
 
|Fauldvincri
 +
|-
 
|Krebin
 
|Krebin
 
|Kyocristine
 
|Kyocristine
 
|Nevexitin
 
|Nevexitin
−
|Oncocristin AQ
+
|Oncovin
−
|Oncovin ELI Lilly
 
−
|Oncovin INJ.LSG.
 
−
|-
 
−
|Oncovin Yamakawa
 
 
|Onkocristin
 
|Onkocristin
−
|P&U Vincristine
 
 
|Pericristine
 
|Pericristine
 
|Pharmacristine
 
|Pharmacristine
 
|Tecnocris
 
|Tecnocris
−
|Trav Vincristine
 
−
|Vero Vincristin
 
 
|-
 
|-
 
|Vincasar
 
|Vincasar
−
|Vincasar PFS
 
 
|Vinces
 
|Vinces
 
|Vincosid
 
|Vincosid
Line 86: Line 108:
 
|Vincrifil
 
|Vincrifil
 
|Vincrin
 
|Vincrin
 +
|Vincrisin
 
|-
 
|-
−
|Vincrisin
 
 
|Vincrisol
 
|Vincrisol
 
|Vincristin
 
|Vincristin
 
|Vincristina
 
|Vincristina
−
|Vincristina Faulding
 
−
|Vincristina Filaxis
 
−
|Vincristina Martian
 
−
|Vincristin Biosyn
 
−
|-
 
−
|Vincristin CS
 
−
|Vincristine
 
−
|Vincristine Abic
 
−
|Vincristine Comp
 
−
|Vincristine DBL
 
−
|Vincristine Lederle
 
−
|Vincristine Mayne
 
−
|Vincristine Mayne Pharma ( BEN )
 
−
|-
 
−
|Vincristine Pharmachemie
 
 
|Vincristinesulfaat
 
|Vincristinesulfaat
−
|Vincristine Sulfate
 
−
|Vincristine Sulfate Synthelabo
 
−
|Vincristine Sulp
 
−
|Vincristine Sulphate
 
−
|Vincristine Teva
 
 
|Vincristinsulfat
 
|Vincristinsulfat
−
|-
 
−
|Vincristin Sulfate
 
 
|Vincristinum
 
|Vincristinum
 
|Vincrisul
 
|Vincrisul
 
|Vinracin
 
|Vinracin
 +
|-
 
|Vinracine
 
|Vinracine
 
|Vinstin
 
|Vinstin
Line 126: Line 127:
 
<references/>
 
<references/>
  
−
[[Category:Drug index]]
+
[[Category:Drugs]]
−
[[Category:Chemotherapy]]
+
[[Category:Intravenous medications]]
−
[[Category:Intravenous chemotherapy]]
+
[[Category:Vesicant]]
−
[[Category:Vesicant chemotherapy]]
 
  
 
[[Category:Microtubule inhibitors]]
 
[[Category:Microtubule inhibitors]]
 
[[Category:Vinca alkaloids]]
 
[[Category:Vinca alkaloids]]
  
−
[[Category:Acute lymphocytic leukemia medications]]
+
[[Category:Adult T-cell leukemia-lymphoma medications]]
−
[[Category:Aggressive Non-Hodgkin lymphoma medications]]
+
[[Category:Anaplastic glioma medications]]
 
[[Category:Anaplastic large cell lymphoma medications]]
 
[[Category:Anaplastic large cell lymphoma medications]]
−
[[Category:Bone cancer medications]]  
+
[[Category:B-cell acute lymphoblastic leukemia medications]]
 
[[Category:Burkitt lymphoma medications]]
 
[[Category:Burkitt lymphoma medications]]
−
[[Category:Central nervous system (CNS) cancer medications]]
+
[[Category:CNS lymphoma medications]]
−
[[Category:Central nervous system (CNS) lymphoma medications]]
 
−
[[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]]
 
 
[[Category:Diffuse large B-cell lymphoma medications]]
 
[[Category:Diffuse large B-cell lymphoma medications]]
−
[[Category:Extranodal NK/T-cell lymphoma, nasal type medications]]
+
[[Category:Ewing sarcoma medications]]
 +
[[Category:Extranodal NK- and T-cell lymphoma, nasal type medications]]
 
[[Category:Follicular lymphoma medications]]
 
[[Category:Follicular lymphoma medications]]
 +
[[Category:Gestational trophoblastic neoplasia medications]]
 +
[[Category:Glioblastoma medications]]
 +
[[Category:Hepatoblastoma medications]]
 
[[Category:HIV-associated lymphoma medications]]
 
[[Category:HIV-associated lymphoma medications]]
−
[[Category:Hodgkin lymphoma medications]]
+
[[Category:Classical Hodgkin lymphoma medications]]
 
[[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]]
 
[[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]]
 +
[[Category:Low-grade glioma medications]]
 +
[[Category:Low-grade glioma, pediatric medications]]
 
[[Category:Mantle cell lymphoma medications]]
 
[[Category:Mantle cell lymphoma medications]]
 
[[Category:Marginal zone lymphoma medications]]
 
[[Category:Marginal zone lymphoma medications]]
 
[[Category:Mediastinal gray-zone lymphoma medications]]
 
[[Category:Mediastinal gray-zone lymphoma medications]]
 +
[[Category:Medulloblastoma medications]]
 
[[Category:Multiple myeloma medications]]
 
[[Category:Multiple myeloma medications]]
−
[[Category:Neuroendocrine tumor medications]]
+
[[Category:Neuroblastoma medications]]
 
[[Category:Penile cancer medications]]
 
[[Category:Penile cancer medications]]
 
[[Category:Peripheral T-cell lymphoma medications]]
 
[[Category:Peripheral T-cell lymphoma medications]]
−
[[Category:Sarcoma medications]]  
+
[[Category:Pheochromocytoma medications]]
−
[[Category:Small cell lung cancer medications]]
+
[[Category:Post-transplant lymphoproliferative disorder‎ medications]]
−
[[Category:Thrombotic thrombocytopenic purpura medications]]
+
[[Category:Primary mediastinal B-cell lymphoma medications]]
 +
[[Category:Rhabdomyosarcoma medications]]
 +
[[Category:Soft tissue sarcoma medications]]
 +
[[Category:T-cell acute lymphoblastic leukemia medications]]
 +
[[Category:Testicular cancer medications]]
 +
[[Category:Acquired thrombotic thrombocytopenic purpura medications]]
 
[[Category:Thymoma medications]]
 
[[Category:Thymoma medications]]
−
[[Category:Transplant medications]]
+
[[Category:Transformed lymphoma medications]]
 +
[[Category:Kaposi sarcoma medications]]
 +
[[Category:Waldenström macroglobulinemia medications]]
 +
[[Category:Wilms tumor medications]]
 +
 
 +
[[Category:Acute myeloid leukemia medications (historic)]]
 +
[[Category:Breast cancer medications (historic)]]
 +
[[Category:Chronic lymphocytic leukemia medications (historic)]]
 +
[[Category:Chronic myeloid leukemia medications (historic)]]
 +
[[Category:Colon cancer medications (historic)]]
 +
[[Category:Head and neck cancer medications (historic)]]
 +
[[Category:Melanoma medications (historic)]]
 +
[[Category:Osteosarcoma medications (historic)]]
 +
[[Category:Small cell lung cancer medications (historic)]]
  
−
[[Category:Drugs FDA approved in 1963]]
+
[[Category:FDA approved in 1963]]
 +
[[Category:EMA approved in 1995]]
 
[[Category:WHO Essential Cancer Medicine]]
 
[[Category:WHO Essential Cancer Medicine]]

Latest revision as of 20:33, 15 July 2024

General information

Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.[1][2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Diseases for which it was used

Notable side effects

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

  • 1995-04-12: EURD

History of changes in PMDA indication

  • 2013-03-25: New additional indication and a new dosage for the treatment of pheochromocytoma.

Also known as

  • Generic names: LCR, leurocristine, VCR, vincristine sulfate
  • Brand names:
Synonyms
Alcrist Biocrist Biocrystin Cellcristin Citomid Crivosin Farmistin CS Fauldvincri
Krebin Kyocristine Nevexitin Oncovin Onkocristin Pericristine Pharmacristine Tecnocris
Vincasar Vinces Vincosid Vincran Vincrex Vincrifil Vincrin Vincrisin
Vincrisol Vincristin Vincristina Vincristinesulfaat Vincristinsulfat Vincristinum Vincrisul Vinracin
Vinracine Vinstin Vintec

References

  1. ↑ 1.0 1.1 Vincristine (Oncovin) package insert
  2. ↑ Vincristine (Oncovin) package insert (locally hosted backup)
  3. ↑ Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010 Nov;11(11):1057-65. Epub 2010 Sep 21. link to original article dosing details in manuscript have been reviewed by our editors PubMed
  4. ↑ Vincristine (Oncovin) patient drug information (Chemocare)
  5. ↑ Vincristine (Oncovin) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Vincristine_(Oncovin)&oldid=89704"